

Applicants: William C. Olson and Paul J. Maddon
Serial No.: 09/594,983
Filed : June 15, 2000
Page 28

EXHIBIT C
Amended Claims

- 98. (Amended) A [The] monoclonal antibody or a fragment thereof [according to claim 78,] comprising complementarity determining regions (CDRs), wherein said CDRs bind to an epitope of chemokine receptor 5 (CCR5) and said epitope comprises amino acid residues in (a) an N-terminus of CCR5, (b) one of three extracellular loop regions of CCR5, or (c) a combination thereof, and wherein the antibody is antibody PA8 (ATCC Accession No. HB-12605), antibody PA9 (ATCC Accession No. HB-12606), antibody PA10 (ATCC Accession No. HB-12607), antibody PA11 (ATCC Accession No. HB-12608), [or] antibody PA12 (ATCC Accession No. HB-12609) or antibody PA14 (ATCC Accession No. HB-12610).--
- 99. (Amended) A hybridoma producing [the] a monoclonal antibody [according to claim 98] comprising complementarity determining regions (CDRs), wherein said CDRs bind to an epitope of chemokine receptor 5 (CCR5) and said epitope comprises amino acid residues in (a) an N-terminus of CCR5, (b) one of three extracellular loop regions of CCR5, or (c) a combination thereof, and wherein the antibody is antibody PA8 (ATCC Accession No. HB-12605), antibody PA9 (ATCC Accession No. HB-12606), antibody PA10 (ATCC Accession No. HB-12607), antibody PA11 (ATCC Accession No. HB-12608), antibody PA12 (ATCC Accession No. HB-12609) or antibody PA14 (ATCC Accession No. HB-12610).--
- 